Microvessel Density in Patients with Cutaneous Melanoma: An Up-to-Date Systematic Review and Meta-Analysis.

IF 1.2 Q3 DERMATOLOGY

Journal of Skin Cancer Pub Date : 2017-01-01 Epub Date: 2017-12-26 DOI:10.1155/2017/2049140

Konstantinos Perivoliotis, Panagiotis Ntellas, Katerina Dadouli, Prodromos Koutoukoglou, Maria Ioannou, Konstantinos Tepetes

{"title":"Microvessel Density in Patients with Cutaneous Melanoma: An Up-to-Date Systematic Review and Meta-Analysis.","authors":"Konstantinos Perivoliotis, Panagiotis Ntellas, Katerina Dadouli, Prodromos Koutoukoglou, Maria Ioannou, Konstantinos Tepetes","doi":"10.1155/2017/2049140","DOIUrl":null,"url":null,"abstract":"Background: We conducted a meta-analysis, in order to appraise the effect of microvessel density (MVD) on the survival of patients with cutaneous melanoma.Methods: This study was conducted according to the PRISMA guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. A systematic literature search in electronic databases (MEDLINE, Web of Science, and Cochrane Central Register of Controlled Clinical Trials) was performed. Fixed Effects or Random Effects model was used, based on the Cochran Q test.Results: In total 9 studies (903 patients) were included. Pooled HR for overall survival (OS) and disease-free survival (DFS) were 2.62 (95% CI: 0.71-9.60, p = 0.15) and 2.64 (95% CI: 0.82-8.47, p = 0.10), respectively. Odds ratios of overall survival between high and low MVD groups, at 12 (1.45, 95% CI: 0.16-13.24), 36 (2.93, 95% CI: 0.63-13.59), and 60 (4.09, 95% CI: 0.85-19.77) months did not reach statistical significance. Significant superiority of low MVD group, in terms of DFS, at all time intervals (OR: 4.69, p < 0.0001; OR: 2.18, p = 0.004; OR: 7.46, p = 0.01, resp.) was documented.Discussion: MVD does not affect the HR of OS and DFS. A strong correlation with DFS rates at 12, 36, and 60 months was recorded.","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2017 ","pages":"2049140"},"PeriodicalIF":1.2000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/2049140","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Skin Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2017/2049140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/12/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 11

Abstract

Background: We conducted a meta-analysis, in order to appraise the effect of microvessel density (MVD) on the survival of patients with cutaneous melanoma.

Methods: This study was conducted according to the PRISMA guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. A systematic literature search in electronic databases (MEDLINE, Web of Science, and Cochrane Central Register of Controlled Clinical Trials) was performed. Fixed Effects or Random Effects model was used, based on the Cochran Q test.

Results: In total 9 studies (903 patients) were included. Pooled HR for overall survival (OS) and disease-free survival (DFS) were 2.62 (95% CI: 0.71-9.60, p = 0.15) and 2.64 (95% CI: 0.82-8.47, p = 0.10), respectively. Odds ratios of overall survival between high and low MVD groups, at 12 (1.45, 95% CI: 0.16-13.24), 36 (2.93, 95% CI: 0.63-13.59), and 60 (4.09, 95% CI: 0.85-19.77) months did not reach statistical significance. Significant superiority of low MVD group, in terms of DFS, at all time intervals (OR: 4.69, p < 0.0001; OR: 2.18, p = 0.004; OR: 7.46, p = 0.01, resp.) was documented.

Discussion: MVD does not affect the HR of OS and DFS. A strong correlation with DFS rates at 12, 36, and 60 months was recorded.

Abstract Image

查看原文本刊更多论文

皮肤黑色素瘤患者的微血管密度:最新的系统回顾和荟萃分析。

背景:我们进行了一项荟萃分析，以评估微血管密度(MVD)对皮肤黑色素瘤患者生存的影响。方法:本研究按照PRISMA指南和Cochrane干预措施系统评价手册进行。在电子数据库(MEDLINE、Web of Science和Cochrane Central Register of Controlled Clinical Trials)中进行系统的文献检索。采用固定效应或随机效应模型，基于Cochran Q检验。结果:共纳入9项研究(903例患者)。总生存期(OS)和无病生存期(DFS)的合并HR分别为2.62 (95% CI: 0.71-9.60, p = 0.15)和2.64 (95% CI: 0.82-8.47, p = 0.10)。高MVD组和低MVD组总生存率的优势比分别为12个月(1.45,95% CI: 0.16-13.24)、36个月(2.93,95% CI: 0.63-13.59)和60个月(4.09,95% CI: 0.85-19.77)，差异无统计学意义。在所有时间间隔内，低MVD组在DFS方面均具有显著优势(OR: 4.69, p < 0.0001;OR: 2.18, p = 0.004;OR: 7.46, p = 0.01，相对而言)。讨论:MVD不影响OS和DFS的HR。与12、36和60个月时的DFS率密切相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Skin Cancer DERMATOLOGY-

CiteScore

2.30

自引率

18.20%

发文量

审稿时长

21 weeks

期刊介绍： Journal of Skin Cancer is a peer-reviewed, Open Access journal that publishes clinical and translational research on the detection, diagnosis, prevention, and treatment of skin malignancies. The journal encourages the submission of original research articles, review articles, and clinical studies related to pathology, prognostic indicators and biomarkers, novel therapies, as well as drug sensitivity and resistance.